Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
35.51
+0.41 (1.17%)
At close: Aug 1, 2025, 4:00 PM
35.51
0.00 (-0.01%)
After-hours: Aug 1, 2025, 4:04 PM EDT
Splunk Revenue
Supernus Pharmaceuticals had revenue of $149.82M in the quarter ending March 31, 2025, with 4.30% growth. This brings the company's revenue in the last twelve months to $668.00M, up 11.82% year-over-year. In the year 2024, Supernus Pharmaceuticals had annual revenue of $661.82M with 8.94% growth.
Revenue (ttm)
$668.00M
Revenue Growth
+11.82%
P/S Ratio
2.94
Revenue / Employee
$991,093
Employees
674
Market Cap
2.22B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 661.82M | 54.30M | 8.94% |
Dec 31, 2023 | 607.52M | -59.72M | -8.95% |
Dec 31, 2022 | 667.24M | 87.46M | 15.09% |
Dec 31, 2021 | 579.78M | 59.38M | 11.41% |
Dec 31, 2020 | 520.40M | 127.64M | 32.50% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 57.37B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SUPN News
- 1 day ago - Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - GlobeNewsWire
- 4 days ago - Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer - GlobeNewsWire
- 10 days ago - Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025 - GlobeNewsWire
- 18 days ago - SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE - Business Wire
- 6 weeks ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc. - PRNewsWire
- 6 weeks ago - Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal - Reuters
- 6 weeks ago - Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio - GlobeNewsWire
- 2 months ago - Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals - GlobeNewsWire